Pasithea Therapeutics (KTTA) Stock Overview
A clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
KTTA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Pasithea Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.13 |
| 52 Week High | US$3.85 |
| 52 Week Low | US$0.28 |
| Beta | 0.21 |
| 1 Month Change | 63.77% |
| 3 Month Change | 46.70% |
| 1 Year Change | -60.21% |
| 3 Year Change | -94.23% |
| 5 Year Change | n/a |
| Change since IPO | -98.41% |
Recent News & Updates
Shareholder Returns
| KTTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.1% | -1.3% | 0.5% |
| 1Y | -60.2% | 16.9% | 12.1% |
Return vs Industry: KTTA underperformed the US Biotechs industry which returned 16.9% over the past year.
Return vs Market: KTTA underperformed the US Market which returned 12.1% over the past year.
Price Volatility
| KTTA volatility | |
|---|---|
| KTTA Average Weekly Movement | 40.2% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: KTTA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KTTA's weekly volatility has increased from 25% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Tiago Marques | www.pasithea.com |
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis.
Pasithea Therapeutics Corp. Fundamentals Summary
| KTTA fundamental statistics | |
|---|---|
| Market cap | US$25.31m |
| Earnings (TTM) | -US$13.49m |
| Revenue (TTM) | n/a |
Is KTTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KTTA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.49m |
| Earnings | -US$13.49m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KTTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/07 11:09 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pasithea Therapeutics Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Constantine Davides | D. Boral Capital LLC. |